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Abstract: Recent studies have shown that vanillin has anti-cancer, anti-mutagenic, and anti-metastatic
activity; however, the precise molecular mechanism whereby vanillin inhibits metastasis and cancer
progression is not fully elucidated. In this study, we examined whether vanillin has anti-cancer and
anti-metastatic activities via inhibition of hypoxia-inducible factor-1α (HIF-1α) in A2058 and A375
human malignant melanoma cells. Immunoblotting and quantitative real time (RT)-PCR analysis
revealed that vanillin down-regulates HIF-1α protein accumulation and the transcripts of HIF-1α
target genes related to cancer metastasis including fibronectin 1 (FN1), lysyl oxidase-like 2 (LOXL2),
and urokinase plasminogen activator receptor (uPAR). It was also found that vanillin significantly
suppresses HIF-1α mRNA expression and de novo HIF-1α protein synthesis. To understand the
suppressive mechanism of vanillin on HIF-1α expression, chromatin immunoprecipitation was
performed. Consequently, it was found that vanillin causes inhibition of promoter occupancy
by signal transducer and activator of transcription 3 (STAT3), but not nuclear factor-κB (NF-κB),
on HIF1A. Furthermore, an in vitro migration assay revealed that the motility of melanoma cells
stimulated by hypoxia was attenuated by vanillin treatment. In conclusion, we demonstrate that
vanillin might be a potential anti-metastatic agent that suppresses metastatic gene expression and
migration activity under hypoxia via the STAT3-HIF-1α signaling pathway.
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1. Introduction
Malignant melanoma is a skin cancer that develops from the abnormal growth and differentiation
of melanocytes with hyperpigmentation; the incidence of melanoma cases has been increasing, and this
particular skin cancer is associated with a high rate of mortality caused by early and rapid metastasis [1].
Significant therapeutic advances have been made using small molecule inhibitors that target melanoma,
but challenges to eradicate these solid tumors still persist.
Given the fact that a hypoxic microenvironment is a major feature in multiple types of solid cancers
including melanoma, hypoxia-inducible factor-1 (HIF-1) composed of α and β subunits is a pivotal
transcription factor in the adaptation of cells to low oxygen conditions. HIF-1α protein is tightly
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regulated by oxygen levels despite the constitutive expression of HIF-1α mRNA. Under normoxic
conditions, HIF-1α gets degraded before it can be translocated to the nucleus, associate with HIF-1β,
and begin the hypoxic response that is conducive to tumor formation. For this degradation to occur,
HIF-1α is hydroxylated by the prolyl 4-hydroxylase (P4H) enzyme into proline 402 and 564 residues,
which cause HIF-1α to bind to the von Hippel-Lindau protein (VHL) E3-ubiquitin ligase complex,
leading to ubiquitination of this complex and subsequent signaling for proteasomal degradation.
Conversely, hypoxic conditions arrest this oxygen-dependent reaction, resulting in the dimerization
of α and β subunits in the nucleus. Additionally, oncogenic signaling pathways such as the PI3K
(phosphoinositide 3-kinase)-AKT-mTOR (mammalian target of rapamycin )axis and mitogen-activated
protein kinase (MAPK) pathway are involved in de novo HIF-1α protein synthesis via 5′-cap-dependent
translation initiation [2,3], and various transcription factors including signal transducer and activator
of transcription 3 (STAT3) and nuclear factor-κB (NF-κB) are critical for regulating HIF-1α mRNA
expression with promoter occupancy at the proximal region of HIF1A [4–7]. The HIF-1α and HIF-1β
complex binds to the hypoxia-response element (HRE), thereby affecting various downstream genes
associated with cancer cell angiogenesis, migration, and metastasis. During cancer metastasis, HIF-1α
in hypoxic microenvironments transcriptionally increases various transcripts related to stimulation of
cell migration and invasion, including fibronectin 1 (FN1), urokinase plasminogen activator receptor
(uPAR), lysyl oxidase-like 2 (LOXL2), and matrix metalloproteinases (MMPs) [8].
Vanillin is a major component of vanilla bean extract and is widely used as a flavoring in
foods. Because of its antioxidant properties, many biological activities of vanillin have been studied.
Vanillin inhibited mutagen induced-DNA damage or spontaneous mutation in bacteria and human
cells by eliciting DNA repair [9–11]. Recent reports have shown that vanillin has anti-cancer
effects through increased apoptosis and cell cycle arrest in melanoma, colon, and cervical cancer
cells [12–14]. In addition, vanillin has also been reported to exhibit anti-invasive and anti-metastatic
activities by suppressing the phosphoinositide 3-kinase (PI3K) and NF-κB signaling pathways in
lung, breast, and liver cancer cells [15–17]. Nevertheless, the precise molecular mechanism by which
vanillin suppresses cancer growth and metastatic potential has not yet been elucidated. Taking into
consideration all of the above facts, this study focused on the role of vanillin in the suppression of
cancer cell motility and the mechanism of HIF-1α inhibition under hypoxic environments in A2058
and A375 malignant melanoma cells.
In the present study, we evaluated the inhibitory effects of vanillin on hypoxia-inducible factor
(HIF)-1α accumulation and cancer cell motility under hypoxia by abrogating STAT3-mediated HIF1A
mRNA expression. Our results suggest that vanillin is a potential therapeutic compound that can be
used to develop anti-metastatic agents or preventive functional foods for malignant melanoma.
2. Results
2.1. Anti-Cancer Effects of Vanillin in Human A2058 and A375 Malignant Melanoma Cells
Because the anti-cancer effect of vanillin under hypoxic conditions has not been previously
reported, we measured cell viability under both normoxia and hypoxia in the absence or presence of
vanillin. Vanillin did not have any significant effect on the viability of A2058 and A375 melanoma cells
under hypoxia (Figure 1).
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Figure 1. Anti-cancer effects of vanillin upon normoxia or hypoxia. Anti-cancer effects of vanillin in 
A375 and A2058 malignant melanoma cells. Cells were incubated with 1.6, 2.5, 3.3, 4.1, and 5.0 mM 
of vanillin for 12 h or 24 h under normoxic (N) or hypoxic (H) condition. Cell viability was measured 
by crystal violet assay as described in the materials and methods section. 
2.2. Vanillin Decreases HIF-1α Protein Levels under Hypoxia in A2058 and A375 Malignant  
Melanoma Cells 
We investigated the inhibitory effect of vanillin on hypoxia-induced HIF-1α accumulation. 
Based on our results, vanillin strongly suppressed hypoxia-induced HIF-1α accumulation, and this 
effect was independent of any toxicity to A2058 and A375 cells (Figure 2A). To determine whether 
vanillin also decreases nuclear HIF-1α protein, we measured nuclear HIF-1α protein levels under 
both normoxia and hypoxia in the absence or presence of vanillin. We found that vanillin inhibits 
HIF-1α accumulation in the nucleus (Figure 2B), suggesting that vanillin could suppress both HIF-
1α transcriptional activity and HIF-1α protein levels. In addition, HIF-1β protein levels were slightly 
increased under vanillin treatment in the cytoplasm, but decreased in the nucleus. Because HIF-1β is 
translocated into the nucleus through its interaction with HIF-1α, the suppression of HIF-1α protein 
levels by vanillin treatment may change HIF-1β protein levels in the cytoplasm and nucleus (Figure 
2B). 
 
Figure 2. Vanillin decreases hypoxia-inducible factor (HIF)-1α protein levels upon hypoxia. (A) 
Vanillin suppresses hypoxia-induced HIF-1α protein levels. Cells were incubated in the absence or 
presence of vanillin for 8 h under normoxic or hypoxic condition. HIF-1α protein levels were 
measured by immunoblotting using anti-HIF-1α antibody; (B) Nuclear HIF-1α protein was decreased 
by vanillin treatment under hypoxia. Protein levels were quantified using Image J 1.49v software 
(National Institutes of Health, Bethesda, MD, USA). Values represent the mean ± standard deviations 
of three independent experiments performed. 
2.3. Vanillin Attenuates HIF-1α Protein Synthesis 
To understand the suppression mechanism of vanillin on HIF-1α accumulation, we investigated 
whether the presence of vanillin could decrease HIF-1α whose increased levels were induced by 
Figure 1. Anti-cancer effects of vanillin upon normoxia or hypoxia. Anti-cancer effects of vanillin in
A375 and A2058 malignant melanoma cells. Cells were incubated with 1.6, 2.5, 3.3, 4.1, and 5.0 mM of
vanillin for 12 h or 24 h under normoxic (N) or hypoxic (H) condition. Cell viability was measured by
crystal violet assay as described in the materials and methods section.
2.2. Vanillin Decreases HIF-1α Protein Levels under Hypoxia in A2058 and A375 alignant Melanoma Cells
We investigated the inhibitory effect of vanillin on hypoxia-induced HIF-1α accumulation.
Based on our results, vanillin strongly suppressed hypoxia-induced HIF-1α accumulation, and this
effect was independent of any toxicity to A2058 and A375 cells (Figure 2A). To determine whether
vanillin also decreases nuclear HIF-1α protein, we measured nuclear HIF-1α protein levels under
both normoxia and hypoxia in the absence or presence of vanillin. We found that vanillin inhibits
HIF-1α accumulation in the nucleus (Figure 2B), suggesting that vanillin could suppress both HIF-1α
transcriptional activity and HIF-1α protein levels. In addition, HIF-1β protein levels were slightly
increased under vanillin treatment in the cytoplasm, but decreased in the nucleus. Because HIF-1β is
translocated into the nucleus through its interaction with HIF-1α, the suppression of HIF-1α protein
levels by vanillin treatment may change HIF-1β protein levels in the cytoplasm and nucleus (Figure 2B).
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the presence of vanill n could ecrease HIF-1α whose increased levels were induced by using
an iron chelator and 26S proteasome inhibition. Consequently, increased HIF-1α expression by both
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iron chelator (Figure 3A) and proteasome inhibitor (Figure 3B), as observed in the control cells, was also
dramatically decreased by vanillin treatment, suggesting that neither hydroxylation nor proteasomal
degradation of HIF-1α is associated with the suppressive effect of vanillin on HIF-1α accumulation.
Therefore, we next investigated whether vanillin could attenuate de novo protein synthesis of HIF-1α.
The results, shown in Figure 3C, demonstrate that vanillin strongly attenuates HIF-1α accumulation
increased by MG132 (which blocks all proteolytic activity of the 26S proteasome complex) after blocking
the de novo synthesis of HIF-1α by using CHX, as protein translation inhibitor, in both A2058 and A375
melanoma cells, suggesting that vanillin causes inhibition of de novo HIF-1α protein synthesis. Because
the mammalian target of rapamycin (mTOR)-mediated phosphorylation of eukaryotic translation
initiation factor 4E-binding protein 1 (4E-BP1), eukaryotic translation initiation factor 4E (eIF4E), and S6
kinase ribosomal protein stimulate de novo HIF-1α protein synthesis [2,3], we further elucidated the
phosphorylation status of 4E-BP1, eIF4E, and S6 kinase after vanillin treatment. From Figure 3D, it was
observed that vanillin does not alter phosphorylation of 4E-BP1, eIF4E, and S6 kinase, suggesting
that mTOR-mediated de novo HIF-1α protein synthesis is not responsible for the reduction of HIF-1α
by vanillin.
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presence of 50 μM of DFO for 6 h; (B) Vanillin suppresses HIF-1α increased by proteasome inhibitor 
(MG132) treatment. Cells were pre-incubated with 2.5 mM of vanillin for 1 h, and then further 
incubated in the absence or presence of 20 μM of MG132 for 6 h; (C) Vanillin attenuates de novo HIF-
1α protein synthesis. Cells were pre-incubated with 100 μM cycloheximide (CHX) for 12 h and then 
washed with phosphate-buffered saline (PBS). Cells were incubated with fresh culture medium 
containing 20 μM of MG132 and 2.5 mM of vanillin (or dimethyl sulfoxide (DMSO)) for indicated 
time. HIF-1α protein levels were detected by immunoblotting, and then protein levels were quantified 
using Image J software; (D) Vanillin does not regulate the signal transduction pathway related to 5′-
cap-dependent translation. 
2.4. Vanillin Decreases HIF-1α mRNA Levels by Inhibiting Promoter Occupancy of STAT3 at HIF1A 
Because decreased mRNA levels also cause retardation of de novo protein synthesis, we next 
measured the HIF-1α mRNA levels after vanillin treatment of A2058 and A375 melanoma cells. We 
found that the HIF-1α mRNA levels were significantly decreased by vanillin treatment (Figure 4A). 
It is becoming clear that STAT3 and NF-κB are critical transcription factors for HIF-1α mRNA 
expression through direct interaction with the proximal promoter of HIF1A [5–7]. Therefore, we 
Figure 3. Vanillin attenuates IF-1α protein synthesis. (A) Vanillin suppresses HIF-1α increased
by treatment with the iron chelator, deferoxamine (DFO), under normoxic condition. A2058 and
A375 cells were pre-incubated with 2.5 mM of vanillin for 1 h, and then further incubated in the
absence or presence of 50 µM of DFO for 6 h; (B) Vanillin suppresses HIF-1α increased by proteasome
inhibitor (MG132) treatment. Cells were pre-incubated with 2.5 mM of vanillin for 1 h, and then further
incubated in the absence or presence of 20 µM of MG132 for 6 h; (C) Vanillin attenuates de novo
HIF-1α protein synthesis. Cells were pre-incubated with 100 µM cycloheximide (CHX) for 12 h and
then washed with phosphate-buffered saline (PBS). Cells were incubated with fresh culture medium
containing 20 µM of MG132 and 2.5 mM of vanillin (or dimethyl sulfoxide (DMSO)) for indicated
time. HIF-1α protein levels were detected by immunoblotting, and then protein levels were quantified
using Image J software; (D) Vanillin does not regulate the signal transduction pathway related to
5′-cap-dependent translation.
2.4. Vanillin Decreases HIF-1α mRNA Levels by Inhibiting Promoter Occupancy of STAT3 at HIF1A
Because decreased mRNA levels also cause retardation of de novo protein synthesis, we next
measured the IF-1α R levels after vanillin treatment of A2058 and A375 melanoma cells.
We found that the HIF-1α mRNA levels were significantly decreased by vanillin treat ent (Figure 4A).
It is becoming clear that STAT3 and NF-κB are critical transcription factors for HIF-1α mRNA
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expression through direct interaction with the proximal promoter of HIF1A [5–7]. Therefore,
we investigated the suppressive effect of vanillin on STAT3 activation and its promoter occupancy on
HIF1A. Vanillin significantly decreases STAT3 phosphorylation in both A2058 and A375 melanoma
cells (Figure 4B). In addition, it was also found that the proximal promoter of HIF1A is dissociated
from STAT3, but not from NF-κB (Figure 4C). These results suggest that the inactivation of STAT3 is
responsible for the decreased HIF-1α levels in response to treatment with vanillin.
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of STAT3 from the HIF-1α promoter region. A2058 cells were incubated with 2.5 mM of vanillin for 8 
h and then fixed with formalin. Chromatin was immunoprecipitated with non-immunized serum 
(IgG) or the antisera as indicated. The proximal region of HIF-1α promoter was amplified using 
quantitative PCR. Values represent the mean ± SD of two independent experiments performed in 
triplicate; * p < 0.05. 
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To determine whether vanillin functionally suppresses HIF-1α transcriptional activity as well as 
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(VEGF)-luciferase) was measured. In this case, vanillin dramatically down-regulates HIF-1α 
promoter activity (Figure 5A) and its target genes involved in glycolytic metabolism (CA-IX, PDK1, 
GLUT1, and LDHA: carbonic anhydrase 9, pyruvate dehydrogenase kinase 1, glucose transporter 1, 
and lactate dehydrogenase A) and cancer metastasis (FN1, LOXL2, and uPAR) under hypoxia in 
A2058 and A375 cells (Figure 5B,C). Because HIF-1α stimulates cancer cell motility and invasiveness 
under hypoxia [8], the inhibitory effect of vanillin on cell migration increased by hypoxia was tested. 
Consequently, it was found that vanillin strongly attenuates cell migration under hypoxia in A2058 
and A375 cells (Figure 5D). These results demonstrate that vanillin suppresses cancer cell motility by 
inhibiting HIF-1α target gene expression associated with cancer metastasis. 
Figure 4. Vanillin decreases HIF-1α mRNA expression by inhibiting signal transducer and activator
of transcription 3 (STAT3). (A) Vanillin decreases HIF-1α mRNA levels in A2058 and A375 human
melanoma cells. Cells were incubated in the absence or presence of vanillin for 8 h or 16 h under
hypoxic condition. HIF-1α mRNA levels were measured using quantitative real time (RT)-PCR.
Values represent the mean ± SD of three independent experiments performed in duplicate; * p < 0.05;
(B) Vanillin decreases STAT3 phosphorylation under hypoxia. A2058 and A375 melanoma cells were
incubated with vanillin for 8 h under hypoxia. STAT3 protein levels were detected by immunoblotting,
and then protein levels were quantified using Image J software. Values represent the mean ± SD of
three independent experiments performed; * p < 0.05; (C) Vanillin causes dissociation of STAT3 from
the HIF-1α promoter region. A2058 cells were incubated with 2.5 mM of vanillin for 8 h and then
fixed with formalin. Chromatin was immunoprecipitated with non-immunized serum (IgG) or the
antisera as indicated. The proximal region of HIF-1α promoter was amplified using quantitative PCR.
Values represent the mean ± SD of two independent experiments performed in triplicate; * p < 0.05.
2.5. Vanillin Down-Regulates HIF-1α Target Gene Expression and Causes Suppression of Cell Motility
To determi e whether vanillin functionally suppresses HIF-1α transcriptional activity as well
as protein levels, HIF-1α responsive promoter activity (HRE- or vascular endothelial growth factor
(VEGF)-luciferase) was measured. In this case, vanillin dramatically down-regulates HIF-1α promoter
activity (Figure 5A) and its target genes involved in glycolytic metabolism (CA-IX, PDK1, GLUT1,
and LDHA: carbonic anhydrase 9, pyruvate dehydrogenase kinase 1, glucose transporter 1, and lactate
dehydrogenase A) and cancer metastasis (FN1, LOXL2, and uPAR) under hypoxia in A2058 and A375
cells (Figure 5B,C). Because HIF-1α stimulates cancer cell motility and invasiveness under hypoxia [8],
the inhibitory effect of vanillin on cell migration increased by hypoxia was tested. Consequently,
it was found that vanillin strongly attenuates cell migration under hypoxia in A2058 and A375 cells
(Figure 5D). These results demonstrate that vanillin suppresses cancer cell motility by inhibiting
HIF-1α target gene expression associated with cancer metastasis.
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3. Discussion 
Because intratumoral hypoxia causes HIF-1α overexpression, genetic alterations of HIF-1α are 
commonly observed in malignant solid cancers and closely associated with treatment failure and 
increased mortality; therefore, it is important to identify HIF-1α inhibitors and test their efficacy as 
anticancer therapeutics [8]. A growing number of HIF-1α inhibitors derived from natural products, 
low molecular weight secondary metabolites produced by plants and microbes, have recently been 
identified as HIF-1α inhibitors [18]. For example, it has been reported that apigenin (4′,5,7-
Figure 5. Vanillin nhibits HIF-1α transcripti l activity and cell motility in m lignant elanoma
cells. (A) Inhibitory effect of vanillin on HIF-1α transcriptional activity. A2058 cells were transiently
transfected with the hypoxia-responsive element (HRE) or vascular endothelial growth factor
(VEGF)–luciferase vector and then incubated for 24 h. Transfected cells were incubated under
normoxia or hypoxia in the absence or presence of vanillin (2.5 mM) for 24 h. Values represent
the mean ± standard deviation of three independent experiments performed in duplicate; * p < 0.05;
(B,C) Vanillin s pp esses hypoxia-induced HIF-1α targ t gene expression. A2058 and A375 cells
were incubated under normoxia or hypoxia in the absence or presence of va illin (2.5 mM) for
24 h. HIF-1α target gene expression was measured using quantitative RT-PCR. Values represent
the mean ± standard deviation of two independent experiments performed in triplicate; * p < 0.05,
** p < 0.01, and *** p < 0.001; (D) Inhibitory effect of vanillin on cell migration. A2058 and A375 cells
were seeded into transwell chambers and incubated under normoxia or hypoxia for 16 h in the absence
or presence of vanillin (2.5 mM). Scale bar representing 200 µm. Migrated cell numbers were counted
and values represent the mean ± standard deviation of two independent experiments performed in
triplicate; * p < 0.05 and ** p < 0.01.
3. Discussion
Because intratumoral hypoxia causes HIF-1α overexpression, genetic alterations of HIF-1α
are commonly observed in malignant s lid cancers and closely associated with treatm nt failure
and increased mortality; t erefore, it is important o identify HIF-1α inhibitors and test their
efficacy as anticancer therapeutics [8]. A growing number of HIF-1α inhibitors derived from
natural products, low molecular weight secondary metabolites produced by plants and microbes,
have recently been identified as HIF-1α inhibitors [18]. For example, it has been reported that
apigenin (4′,5,7-trihydroxyflavone) and resveratrol (trans-3,4,5′-trihydroxystilbene) promote HIF-1α
protein degradation in a manner that is independent of the microenvironment oxygen levels [19,20].
Pleurotin and genistein (4′,5,7-Trihydroxyisoflavone) inhibit the accumulation of HIF-1α protein by
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suppressing protein synthesis under both normoxic and hypoxic conditions [21,22]. Many of the
currently identified HIF-1α inhibitors derived from natural products affect protein accumulation or
degradation. Interestingly, we propose that vanillin may be a promising HIF-1α inhibitor that acts to
reduce HIF-1α levels by suppressing HIF-1α mRNA expression.
Vanillin, a widely used flavoring agent from vanilla, has been shown to exhibit multiple biological
effects, including anti-cancer, anti-mutagenic, and anti-bacterial activity in mammalian cells [9,14,23].
In this study, we demonstrate that vanillin effectively decreases HIF-1α protein levels and the
expression of its target genes related to cell motility, angiogenesis, and glycolytic metabolism in
A2058 and A375 malignant melanoma cells.
To understand the precise molecular mechanism by which vanillin decreases HIF-1α protein
levels, we investigated whether vanillin attenuates HIF-1α protein synthesis or promotes proteasomal
degradation. We found that vanillin dramatically attenuates de novo HIF-1α protein synthesis.
In addition, MG132, a 26S proteasome inhibitor, did not rescue vanillin-mediated HIF-1α reduction
in melanoma cells, suggesting that vanillin reduces HIF-1α using a mechanism that is independent
of proteasomal degradation. Because the growth factor-mediated PI3K-mTOR signaling pathway
activates HIF-1α protein synthesis via 4E-BP1, eIF4E, and S6 kinase linked 5′-cap-dependent translation
initiation [2,3], we tested whether vanillin regulates the phosphorylation status of 4E-BP1, eIF4E, and S6
kinase using torin1, a selective mTOR inhibitor, as a positive control. Unlike torin1, vanillin did not alter
the phosphorylation status of 4E-BP1, eIF4E, and S6 kinase, suggesting that vanillin does not participate
in PI3K-mTOR-mediated protein synthesis. Therefore, we further investigated the inhibitory effect of
vanillin on HIF-1α mRNA expression. Interestingly, HIF-1α mRNA was significantly decreased by
vanillin treatment in A2058 melanoma cells.
How does vanillin decrease HIF-1α mRNA expression? To answer this question, we investigated
the inhibitory effect of vanillin on STAT3-mediated HIF-1α mRNA expression, because STAT3 is one of
the transcription factors that is associated with the proximal promoter of HIF1A [5,6]. Vanillin reduces
STAT3 phosphorylation and promoter occupancy on the 5′-flank of HIF1A. These results suggest that
vanillin decreases HIF-1α by suppressing STAT3-mediated transcription. Nevertheless, we did not
provide a precise molecular mechanism to explain how vanillin inhibits STAT3 phosphorylation and
proximal promoter occupancy on the 5′ flanking region of HIF1A. Therefore, how vanillin suppresses
STAT3 phosphorylation and transcriptional activity should be further investigated.
Although the anti-metastatic effect of vanillin by inhibiting MMP-9 expression in breast and
hepatocellular carcinoma cells has recently been reported, the molecular mechanism by which vanillin
attenuates migration and invasion in cancer cells is not fully demonstrated [15–17]. In the present
study, we provide insight into some part of the mechanism that involves the STAT3-HIF-1α axis on
the vanillin-mediated suppression of cancer cell migration and invasion. Indeed, cell migration was
significantly decreased by vanillin by approximately 50% under normoxic condition. Under hypoxia,
vanillin suppressed cell migration by approximately 75%, suggesting that vanillin could sensitively
block cell motility in malignant tumors with hypoxic microenvironments.
On the basis of previous studies of the anti-metastatic effects of millimolar-range vanillin used to
treat cells in vivo, mice were administered 100 mg/kg/day vanillin. Although 100 mg/kg/day can be
regarded as a high concentration, no side effects were observed [17]. Variable concentrations below
100 mg/kg/day can be considered for animal studies. Several methods can be used to determine the
effects low-concentration vanillin. Vanillin derivatives can be developed to improve delivery efficacy at
low concentrations, which are more effective for preventing malignant melanoma metastasis. Indeed,
a recent report showed that 60 mg/kg/day of o-vanillin, a vanillin isomer, strongly suppressed tumor
growth in mice bearing A375 human malignant melanoma xenografts [14]. For clinical application,
it should be further evaluated whether o-vanillin has anti-metastatic effects via the inhibition of HIF-1α
accumulation. In addition, vanillin may be useful as a functional food and not limited to chemotherapy.
Our results provide a foundation for further analysis of vanillin for the prevention and treatment of
malignant melanoma.
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4. Materials and Methods
4.1. Reagents and Antibodies
Vanillin (V1104), deferoxamine (D9533), MG132 (M7449), dimethyl sulfoxide (DMSO), protease
inhibitor cocktail, and cycloheximide (01810) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Antibodies against 4E-BP1 (9452), phospho-4E-BP1 (2855), eIF4E (9742), phospho-eIF4E (9741),
phospho-S6 (4857), STAT3 (12640), and phospho-STAT3 (9131) were obtained from Cell Signaling
Technology (Danvers, MA, USA). Antibodies against β-tubulin (sc-9104) and β-actin (sc-47778) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HIF-1α and anti-HIF-1β
antibodies were kindly provided by Jong-Wan Park of Seoul National University, Seoul, Korea.
4.2. Cell Culture and Treatment
A2058 and A375 melanoma cell lines were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) and 25 mM glucose in
a humidified atmosphere of 5% CO2 at 37 ◦C. The oxygen level in the hypoxia incubator chamber
was maintained at 1% by continuously injecting N2 gas. Vanillin at various stock concentrations
(0.8, 1.6, 2.5 M) was dissolved in dimethyl sulfoxide (DMSO) and diluted into culture medium prior
to treatment.
4.3. Cell Viability Assay
To determine the cell viability, we used crystal violet staining in this study. Cells were seeded in
24-well plates, and incubated for 24 h, followed by treatment with vanillin in increasing concentrations
for 12 and 24 h at 20% (normoxia) or 1% (hypoxia) oxygen conditions. The cells were fixed with
4% paraformaldehyde for 15 min and stained with 0.05% crystal violet staining solution (HT90132,
Sigma-Aldrich) for 15 min. To measure optical density, 1% sodium dodecyl sulfate (SDS) solution was
added to the cells, and these were further incubated for 15 min at room temperature. The dissolved
solutions were transferred to a 96-well plate and measured at 595 nm using a microplate reader (BioTek,
Winooski, VT, USA).
4.4. Cytosolic and Nuclear Extract Preparation
Cells were washed using cold phosphate-buffered saline and harvested by centrifugation at
1000 rpm for 5 min at 4 ◦C. The harvested cell pellets were resuspended and incubated with ice-cold
buffer A (20 mM Tris at pH 7.8, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM ethylenediaminetetraacetic acid
(EDTA), 0.5 mM dithiothreitol (DTT), and protease inhibitor cocktail) for 5 min on ice, and then cells
were collected by centrifugation at 1000 rpm for 5 min at 4 ◦C. Next, the cell pellets were lysed using
0.06% NP-40 containing buffer A for 10 min on ice. The cell lysates were centrifuged at 3000 rpm
for 5 min, and then the supernatants containing cytosolic proteins were frozen. After obtaining the
cytosolic fraction, the pellets were incubated and lysed using buffer B (20 mM Tris-Cl at pH 7.8, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and 20% glycerol) containing 400 mM NaCl for 30 min on ice.
During incubation, the cells were homogenized with a glass homogenizer. The incubated samples were
centrifuged at 14,000 rpm for 30 min at 4 ◦C, and then supernatants containing the nuclear proteins
were transferred into fresh tubes.
4.5. Immunoblotting
Total proteins were extracted using cell lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris
pH 7.4, 2 mM EDTA, and protease inhibitor cocktail). Cell lysates were separated by 7.5% or
10% SDS-polyacrylamide gel electrophoresis (PAGE). Separated proteins were transferred onto an
Immobilon-P membrane (Millipore, Billerica, MA, USA). The transferred membranes were blocked
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with 5% skim milk in Tris-buffered saline containing 0.05% Tween-20 (TBS-T) for 1 h at room
temperature, and then incubated overnight with primary antibodies diluted at 1:1000 or 1:5000
in 5% skim milk in TBS-T at 4 ◦C. Horseradish peroxidase-conjugated secondary antibodies were
incubated for 1 h at room temperature, and then protein levels were visualized using an Enhanced
Chemiluminescence Prime kit (GE Healthcare, Little Chalfont, UK).
4.6. Quantitative Real-Time PCR
Total RNA was isolated with TRIzol and 2 µg of this RNA was used to synthesize cDNA using
a high capacity cDNA reverse transcription kit (Applied Biosystems). The cDNA was amplified over
40 cycles (95 ◦C for 15 s, 60 ◦C for 1 min). Experimental Cq values were normalized to H36B4 and
relative mRNA levels were calculated on the basis of H36B4 mRNA levels. The sequences of the PCR
primers (5′–3′) were: ATGGAGCCCAGCAGCAA and GGCATTGATGACTCCAGTGTT for GLUT1;
CCACTCCAGCAGGGAAGG and GCGACGCAGCCTTTGAAT for CA-IX; TGAACATTCTGGCT
GGTGACAGGA and ATGATGTCATTCCCACAATGGCCC for PDK1; CTACCTCCACCATGCCAAGT
and AGCTGCGCTGATAGACATCC for VEGF; CCATAAAGGGCAACCAAGAG and ACCTCGG
TGTTGTAAGGTGG for FN1; CACTGCGGATCCCTGAAAC and CCTGTCTTCGGGCTGATG for
LOXL2; AGCCTTACCGAGGTTGTGTG and AAATGCATTCGAGGTAACGG for uPAR.
4.7. In Vitro Migration Assay
In vitro cell migration assays were performed using a Transwell chamber from Sigma-Aldrich
(St. Louis, MO, USA). The underside of the Transwell insert membrane was coated with collagen
and incubated at room temperature until it was dry. Cells in 0.1 mL of fetal bovine serum-free
medium were seeded into the upper chamber, and the lower chamber was filled with 6% fetal bovine
serum-containing medium as a chemotactic source, and then cells were incubated for 16 h at 37 ◦C.
After incubation, the Transwell chambers were quickly washed using phosphate-buffered saline and
stained with hematoxylin and eosin. The Transwell insert membranes, containing the migrated cells,
were placed on a slide glass and analyzed using a microscope (Olympus, Tokyo, Japan). To quantify
the migrated cell numbers, two random fields under 40×magnification were quantified by counting
the cell numbers.
4.8. Chromatin Immunoprecipitation
Cultured cells were fixed with 1% formaldehyde to cross-link chromatin and proteins, and soluble
chromatin and protein complex samples were incubated overnight at 4 ◦C with antibodies against
STAT3 and NF-κB p65. STAT3 or NF-κB p65 interacting DNA was eluted, and then occupancy of STAT3
on the proximal region of the HIF-1α promoter was measured using quantitative PCR. The sequences
of PCR primers for the quantitative ChIP assay (5′–3′) are ATCTGAGCAACGAGACCAAA
and CACGTGCTCGTCTGTGTTTA.
4.9. Luciferase Activity Assay
Hypoxia-responsive element (HRE) or VEGF (vascular endothelial growth factor)
promoter-luciferase reporter plasmids were a gift from Navdeep Chandel (Addgene plasmid
# 26731) and Jong-Wan Park (Seoul National University, Korea). Cells were transfected with reporter
plasmids using Polyfect (QIAGEN, Valencia, CA, USA) and then incubated for 48 h for stabilization.
After incubation, luciferase activity was measured using a luminometer (Berthold Technologies,
Bad Wildbad, Germany) and normalized against β-gal activities to account for transfection efficiency.
4.10. Statistical Analysis
All data were analyzed using an unpaired Student’s t-test for two experimental comparisons and
a one-way ANOVA (analysis of variance) followed by Tukey’s post hoc test for multiple comparisons
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using GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA, USA). Data are represented as
means ± standard deviations (SDs). Differences between mean values were considered statistically
significant when the associated p-value was less than 0.05.
5. Conclusions
In the present study, the major findings were that vanillin: (i) decreases HIF-1α protein levels and
that this effect is independent of proteasomal degradation; (ii) suppresses STAT3 phosphorylation
and its promoter occupancy on the proximal region of HIF-1α; and (iii) attenuates cell migration by
down-regulating HIF-1α target genes associated with cancer metastasis in A375 and A2058 human
malignant melanoma cells. Taken together, these results may provide useful information for the
development of vanillin derivatives as anti-metastatic agents or functional foods for preventing
malignant melanoma metastasis.
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Abbreviations
HIF-1α Hypoxia-inducible factor-1α
STAT3 Signal transducer and activator of transcription 3
NF-κB Nuclear factor-κB
FN1 Fibronectin 1
LOXL2 Lysyl oxidase-like 2
uPAR Urokinase plasminogen activator receptor
VHL Von Hippel-Lindau protein
MAPK Mitogen activated protein kinase
HRE Hypoxia-response element
MMPs Matrix metalloproteinases
PI3K Phosphoinositide 3-kinase
mTOR Mammalian target of rapamycin
4E-BP1 Eukaryotic translation initiation factor 4E-binding protein 1
eIF4E Eukaryotic translation initiation factor 4E
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